Download PharmaEngine Announces Filing New Drug Application (NDA) of

Press Release
PharmaEngine Announces Filing New Drug Application (NDA) of MM-398 (PEP02) to
Taiwan FDA as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Taipei, Taiwan, June 1, 2015 -- PharmaEngine, Inc. (TWO:4162) today announced that a New Drug
Application (NDA) has been submitted to the Taiwan Food and Drug Administration (TFDA) for MM-398
(irinotecan liposome injection, also known as nal-IRI) in patients with metastatic adenocarcinoma of the
pancreas who have been previously treated with gemcitabine-based therapy. The filing of MM-398 to the
TFDA follows the recent submissions of NDA and marketing authorization application (MAA) by its
licensing partner, Merrimack Pharmaceuticals, Inc. （NASDAQ：MACK）and its sublicensing partner,
Baxter International’s BioScience business (NYSE: BAX) to the US FDA and to the European Medicines
Agency (EMA), respectively.
The filing of MM-398 to the TFDA was supported by the positive data from a phase 3 study (NAPOLI-1)
conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based
therapy. “This submission represents a significant milestone in the history of PharmaEngine. We are
extremely grateful to our investigators, patients and their caregivers for their participation in making
Taiwan the top recruitment country in this pivotal study. We are also thankful for the support from
Merrimack in preparing our NDA,” said C. Grace Yeh, Ph.D., President and CEO of PharmaEngine. “We
look forward to working with our regulatory authority to offer a new treatment option to help the patients in
fighting against their pancreatic cancer.”
About MM-398 (PEP02)
MM-398 (PEP02, irinotecan liposome injection), also known as “nal-IRI,” is a novel, stable
nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. In May 2011,
PharmaEngine and Merrimack executed an exclusive license agreement. Under the terms of the
agreement, PharmaEngine granted back Merrimack the rights to develop, manufacture, and
commercialize PEP02 (designated as MM-398 by Merrimack) in Asia and Europe, and retained the same
rights in Taiwan. In September 2014, Merrimack licensed the rights to MM-398 outside of the US and
Taiwan to Baxter International’s BioScience business. In 2011, MM-398 received orphan drug designation
from both the US FDA and EMA for the treatment of pancreatic cancer. In addition, MM-398 received Fast
Track Designation for post-gemcitabine metastatic pancreatic cancer from the US FDA in November 2014,
and completed the rolling submission of the NDA for US FDA in April 2015 and the MAA to EMA in May
2015.
1
Press Release
About NAPOLI-1 Study
The global, randomized, open label phase 3 study, referred to as NAPOLI-1 (NAPOLI acronym:
NAnoliPOsomaL Irinotecan), was sponsored by Merrimack Pharmaceuticals, Inc. (Cambridge, MA, USA).
Patients were recruited from over 100 sites in 15 countries (North America, South America, Europe, Asia
and Australia). The total enrollment of 417 patients were randomized across the three arms: MM-398
2
2
(120 mg/m , every three weeks) as a monotherapy, MM-398 (80 mg/m , every two weeks) in combination
with 5-FU/LV, and a shared control arm of 5-FU/LV.
MM-398 in combination with 5-fluorouracil (5-FU)
and leucovorin (LV) achieved the primary and secondary endpoints by demonstrating a clinically and
statistically significant improvement in overall survival, progression free survival and overall response rate
compared to the control group of patients who received a combination of 5-FU and LV. This was the first
global phase 3 study in a post-gemcitabine setting showing a survival benefit in this aggressive disease.
About PharmaEngine, Inc. (TWO: 4162)
PharmaEngine is a biopharmaceutical company established in Taipei, Taiwan. PharmaEngine focuses on
the development of new medications for the treatment of cancer and Asian prevalent diseases.
PharmaEngine has three projects: PEP02 (MM-398) in NDA stage; PEP503 (NBTXR3) in a global pivotal
trial of soft tissue sarcoma; and PEP06 in drug discovery. For further information, please visit
PharmaEngine’s website at http://www.pharmaengine.com.
Contact
Peter Wu, Director, Corporate Development
Telephone No.: (+886)-2-2515-8228, ext. 500
Mobile phone No.: (+886)-935-154-559
Email: [email protected]
2